Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Cash & Equivalents: 2018-2025

  • Dr Reddys Laboratories' Cash & Equivalents rose 102.35% to $172.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $172.0 million, marking a year-over-year increase of 102.35%. This contributed to the annual value of $172.0 million for FY2025, which is 102.35% up from last year.
  • As of Q1 2025, Dr Reddys Laboratories' Cash & Equivalents stood at $172.0 million, which was up 102.35% from $85.0 million recorded in Q1 2024.
  • Dr Reddys Laboratories' Cash & Equivalents' 5-year high stood at $203.0 million during Q1 2021, with a 5-year trough of $70.0 million in Q1 2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $85.0 million (2024), whereas its average is $109.0 million.
  • Per our database at Business Quant, Dr Reddys Laboratories' Cash & Equivalents soared by 651.85% in 2021 and then slumped by 64.29% in 2023.
  • Quarterly analysis of 5 years shows Dr Reddys Laboratories' Cash & Equivalents stood at $203.0 million in 2021, then dropped by 3.45% to $196.0 million in 2022, then tumbled by 64.29% to $70.0 million in 2023, then rose by 21.43% to $85.0 million in 2024, then surged by 102.35% to $172.0 million in 2025.
  • Its Cash & Equivalents was $172.0 million in Q1 2025, compared to $85.0 million in Q1 2024 and $70.0 million in Q1 2023.